This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Silk Road Medical Past Earnings Performance

Past criteria checks 0/6

Silk Road Medical's earnings have been declining at an average annual rate of -3.1%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 26.1% per year.

Key information

-3.1%

Earnings growth rate

23.3%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate26.1%
Return on equity-36.6%
Net Margin-29.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Silk Road Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2OW Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24191-5716043
31 Mar 24185-5315242
31 Dec 23177-5614541
30 Sep 23170-5513840
30 Jun 23163-5313139
31 Mar 23151-5512339
31 Dec 22139-5511636
30 Sep 22127-5711135
30 Jun 22114-6110833
31 Mar 22107-5610230
31 Dec 21101-509627
30 Sep 2194-529030
30 Jun 2190-488427
31 Mar 2178-487724
31 Dec 2075-477621
30 Sep 2073-397314
30 Jun 2070-377113
31 Mar 2070-386913
31 Dec 1963-526312
30 Sep 1956-605712
30 Jun 1949-614912
31 Mar 1942-564211
31 Dec 1835-383510
31 Dec 1714-19207

Quality Earnings: 2OW is currently unprofitable.

Growing Profit Margin: 2OW is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2OW is unprofitable, and losses have increased over the past 5 years at a rate of 3.1% per year.

Accelerating Growth: Unable to compare 2OW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2OW is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.2%).


Return on Equity

High ROE: 2OW has a negative Return on Equity (-36.55%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/17 14:01
End of Day Share Price 2024/09/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Silk Road Medical, Inc is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Joanne WuenschBMO Capital Markets Equity Research
Travis SteedBofA Global Research